filgotinib (Jyseleca)
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
- nasopharyngitis (10%)
- 4 uncomplicated herpes zoster cases
- 1 retinal vein occlusion
- no opportunistic infections, active tuberculosis, malignancies, GI perforations, or deaths
- possible impact on sperm parameters (held up FDA approval)[2]
- potential toxicities seen at a high 200 mg dose[2]
Mechanism of action
- JAK1 inhibitor
Notes
- Galapagos sole developer[2]
More general terms
References
- ↑ Genovese MC, Kalunian K, Gottenberg JE et al Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease- Modifying Antirheumatic Drug TherapyThe FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315-325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334793 https://jamanetwork.com/journals/jama/fullarticle/2738551
Singh JA Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA. 2019;322(4):309-311 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334773 https://jamanetwork.com/journals/jama/fullarticle/2738528 - ↑ 2.0 2.1 2.2 2.3 Gever J Filgotinib Maintains RA Efficacy for 3 Years, No New Safety Issues. Looks like FDA blew the call on selective JAK1 inhibitor. MedPage Today October 28, 2024 https://www.medpagetoday.com/rheumatology/arthritis/112618